SANUWAVE's PACE Data to be Presented at the 2013 World Congress of Microsurgery

ALPHARETTA, Ga., July 10, 2013 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that pre-clinical results using the Company's patented Pulsed Acoustic Cellular Expression (PACE®) technology, which uses focused high-energy acoustic shock waves, will be presented by Dr. Maria Siemionow in an oral presentation at the 2013 World Congress of Microsurgery. The international meeting will be held from July 11-14, 2013 in Chicago, Illinois.

Maria Siemionow, MD, PhD, is a world-renowned scientist and microsurgeon. She is the Director of Plastic Surgery Research and Head of Microsurgical Training at Cleveland Clinic's Department of Plastic Surgery. Dr. Siemionow specializes in microsurgery, hand surgery, peripheral nerve surgery, transplantation, and microcirculation research. Dr. Siemionow received the first IRB approval in the world for her face transplant protocol and, in 2008, led a team of surgeons in performing the first face transplant in the United States.

**Paper Title:** Pre- and Postischemic Extracorporeal Shock Wave Conditioning Modulates Expression of Inflammatory Factors in Cremaster Ischemia/Reperfusion Injury Model

**Presentation ID:** 1647

**Session Title:** Microsurgical Basic Science Research

**Session Time:** Saturday, July 13: 9:00 - 10:30 am

More information about the World Congress of Microsurgery can be found at [www.wsrm2013.org](http://www.wsrm2013.org).

About the PACE Technology
SANUWAVE's patented Pulsed Acoustic Cellular Expression (PACE®) technology utilizes high-energy acoustic pressure waves in the shock wave spectrum to produce compressive and tensile stresses on cells and tissues to elicit a series of biological responses. PACE therapy is a novel, non-invasive, and potentially cost-effective method to accelerate the healing of wounds and damaged tissues. PACE acts via vascular, inflammatory, and tissue regeneration components. Cells are activated to produce wound healing proteins which initiate a cascade of activities which leads to tissue repair. The mechanical stimulation of these cells causes growth factor upregulation, blood vessel widening (arteriogenesis), blood vessel proliferation (angiogenesis), and a modulated inflammatory response, all leading to the subsequent regeneration of skin, musculoskeletal, and vascular tissue. PACE has also been shown to cause biofilm disruption.

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE intends to apply its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe and Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the
forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit www.sanuwave.com.

CONTACT: DC Consulting, LLC
407-792-3333
investorinfo@dcconsultingllc.com

CAP Strategies, LLC
215-340-1241
lisa.caperelli@gmail.com

Source: SANUWAVE Health, Inc.